Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.

J Immunother Cancer · 2022 · PMC8753441 · PMID 35017153

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

In addition, mIgG1 and mIgG1-N297A tended to increase CD8 and CD4 TILs ( figure 6E , online supplemental figure S8A ), while mIgG2a showed a clear trend towards a decreased CD8:Treg ratio ( figure 6F ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.